FDA approves anti-inflammatory drug Lodoco to treat cardiovascular disease

The FDA green­light­ed on Tues­day an an­ti-in­flam­ma­to­ry drug de­signed to re­duce the risks re­lat­ed to car­dio­vas­cu­lar dis­ease.

Agepha Phar­ma, a Dubai-based phar­ma, se­cured the ap­proval for Lodoco, al­so known as colchicine. Ac­cord­ing to the com­pa­ny, it is the first an­ti-in­flam­ma­to­ry athero­pro­tec­tive treat­ment to re­ceive FDA ap­proval. It was shown to re­duce the risk of heart at­tack, stroke and car­dio­vas­cu­lar death in adults at risk for car­dio­vas­cu­lar dis­ease. The drug will be avail­able via pre­scrip­tions start­ing in the sec­ond half of the year, Agepha said in a re­lease.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN